Portuguese 
An Indaiatuba worker gains 100 direct jobs with the R$86 million that the development bank just released for a pharmaceutical raw material factory, in a ten thousand square meter complex that will only be ready in August 2028.
The operation was approved by BNDES and announced on Monday, September 7.
The funding will go to CYG Biotech, a company of the Blanver Group, which aims to expand its production of active pharmaceutical ingredients.
Active pharmaceutical ingredient is the substance that actually has an effect within the tablet. The rest is excipient.
-
Transpetro Offers 4,171 Job Openings with Initial Salaries of Up to R$15,000; Exam Scheduled for November 29
-
Farmers and Fishermen Affected by Dam Failure in Mariana Receive R$ 1.52 Billion in Income Transfers from a Total of R$ 3.35 Billion since the 2015 Disaster
-
Wineries Can Submit Samples for the Second National Selection of BRS Lorena Grape Wines Starting Tuesday, September 8
-
Inmetro Announces Deadline for Pronametro Scholarships in IoT, Biomaterials, LED Lighting, and Other Technical Areas
One Hundred Direct Jobs Reflect an 80% Growth in Workforce
The absolute number may seem modest until a comparison is made.
The expansion is expected to create 100 direct jobs, which represents an 80% increase over the current workforce, plus another 100 indirect jobs, according to the bank.
In other words, the company nearly doubles its staff with just one new unit.
These positions will have technical profiles related to chemical plant operations, quality control, and regulatory assurance, requiring specific training and health certification.
Half of the Funding Has Mandatory Destination
This detail distinguishes a development financing from a typical loan.
Of the approved amount, half must be used to purchase capital goods produced in Brazil, according to BNDES.
In practice, this ensures that the multiplier effect remains in the country. The reactor, tank, and packaging line must come from local manufacturers, generating activity in a secondary supply chain, far from Indaiatuba.
The Resources Come from BNDES Mais Inovação
The operation was classified under the BNDES Mais Inovação program, aimed at projects that enhance technological capacity, rather than simply increasing production volume.
This distinction is not bureaucratic. Financing more of the same is one thing; financing the local production of an ingredient that currently comes from abroad is another.
This is precisely where the public interest of the project lies.
Subsidized financing comes at a cost to society, so the expected return is precisely that: capacity that the country did not have, rather than just more units of something that was already being produced.
Ten Thousand Square Meters and Two New Buildings
The company will construct a new production complex with a total built area of 10 thousand square meters.
Two buildings will be erected to house the production units, within a project that has a 24-month execution timeline.
The expectation is that the plant will be fully operational by August 2028.
While twenty-four months may seem lengthy for ten thousand square meters, a pharmaceutical plant is not measured simply by construction. The timeline includes equipment qualification, process validation, and health approval.
The List of Treated Diseases Explains the Size of the Investment
The products that will come from there are not niche.
According to BNDES, the facility will produce raw materials for medications used in arthritis, rheumatism, depression, bipolar disorder, cancer, chronic inflammatory diseases, hypertension, stroke, and peripheral artery disease, among others.
This is a list of chronic conditions that consume the most continuous-use medication in Brazil, meaning demand that does not fluctuate with the seasons.
Many of these medications enter public distribution programs, which means recurring purchases from the State and predictable volume for the ingredient producers.
Why Producing Active Pharmaceutical Ingredients in Brazil Has Become a Security Issue
The country produces a lot of medication and imports a significant portion of the active ingredients, especially from Asia.
When the global supply chain stalled during the pandemic, this dependency surfaced starkly: factory set up, packaging ready, and no raw materials to start production.
Since then, financing for domestic active pharmaceutical ingredients has ceased to be merely an industrial policy and has also become a supply policy.
We have seen firsthand what happens when this end fails: there is a shortage of continuous-use medication at pharmacies, and having a pill factory is of no use if the active ingredient is stuck on a ship on the other side of the world.
What the announcement does not reveal
BNDES (Brazil’s development bank) disclosed the amount of the financing, but not the total investment value of the company, which may exceed the approved R$ 86 million (about US$16 million).
There is also no detail on which specific inputs will enter the line first, nor on the production capacity in tons or batches.
All data for this article comes from the bank’s own announcement, which is the sole source in this case.
Indaiatuba Joins an Existing Circuit
The city is located in the Campinas region, which is home to hubs of technology, pharmaceuticals, and research, with universities and R&D centers in the vicinity.
Establishing an active ingredient plant there means competing for qualified labor in a market that is already heated, and we often see this type of project drive salaries up in the region.
Operational positions are not expected to be available until around 2028, when the plant begins operations.
The bank has been concentrating resources in this area: in September, Finep also allocated R$ 215 million for innovation in mineral transformation.
There is also a less discussed chain effect. Producing active ingredients in the country shortens the restocking time for pharmaceutical manufacturers, which currently operate with months of lead time due to maritime transport.
A smaller inventory means lower working capital, and lower working capital translates to slightly cheaper medications at the end. The gain is neither immediate nor guaranteed, however, it is the logic that underpins the financing.
The details of the operation can be found in the BNDES News Agency announcement.
What do you think: can Brazil produce its own active ingredient or will it continue importing from Asia?
